AI Article Synopsis
Article Abstract
Background: BDNF exon IV promoter methylation is a potential biomarker for treatment response to antidepressants in MDD. We have previously shown CpG-87 methylation as a successful biomarker for the prediction of non-response to monoaminergic antidepressants like the SSRI Fluoxetine or the SNRI Venlafaxine. This study aimed to dissect the biological evidence and mechanisms for the functionality of CpG-87 methylation in a cell culture model.
Results: We observed a significant interaction between methylation and antidepressant-mediated transcriptional activity in BDNF exon IV promoter. In addition, antidepressant treatment increased the promoter methylation in a concentration-dependent manner. Further single CpG methylation of -87 did not change the promoter activity, but methylation of CREB domain CpG-39 increased the transcriptional activity in an antidepressant-dependent manner. Interestingly, DNMT3a overexpression also increases the BDNF exon IV transcription and more so in Venlafaxine-treated cells.
Conclusions: The study strengthens the previously reported association between antidepressant treatment and BDNF exon IV promoter methylation as well as hints toward the mechanism of action. We argue that potential CpG methylation biomarkers display a complex synergy with the molecular changes at the neighboring CpG positions, thus highlighting the importance of epiallele analyses.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9793565 | PMC |
| http://dx.doi.org/10.1186/s13148-022-01415-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Plasma Brain-Derived Neurotrophic Factor (BDNF) Levels and BDNF Promoters' DNA Methylation in Workers Exposed to Occupational Stress and Suffering from Psychiatric Disorders.
Brain Sci
October 2024
Center for Work-Related Stress and Occupational Mental Disorders, Azienda Ospedaliero-Universitaria Pisana, 56124 Pisa, Italy.
Article Synopsis
- The study investigates the relationship between plasma BDNF levels and DNA methylation of BDNF promoters in individuals suffering from work-related stress disorders and compares these findings to healthy controls.
- Results indicate that patients with major depressive disorder (MDD) and adjustment disorders (AD) have higher levels of pBDNF compared to controls, with MDD patients showing lower pBDNF levels than AD patients.
- The findings suggest that altered BDNF levels and promoter methylation may play significant roles in stress-related disorders, hinting at a protective response in some cases, but also a potential vulnerability to severe illness under stress.
Selective Noradrenergic Activation of BDNF Translation by Mirtazapine.
Mol Neurobiol
November 2024
Department of Life Sciences, University of Trieste, Via Licio Giorgieri, 5 (Q Building), 34127, Trieste, Italy.
Antidepressants are known for their neurotrophic effects, particularly through the regulation of brain-derived neurotrophic factor (BDNF) expression. Mirtazapine, a tetracyclic noradrenergic and specific serotonergic antidepressant (NaSSA) has been observed to upregulate BDNF, though its underlying mechanism remains unclear. In this study, we used the human neuroblastoma SH-SY5Y cell line to investigate whether mirtazapine could enhance BDNF translation by modulating serotonin and/or norepinephrine and their receptors.
View Article and Find Full Text PDFBDNF methylation associated with stress in women: Novel insights in epigenetics and inflammation.
Brain Behav Immun Health
December 2024
Department of Pathology, Graduate Program in Pathology, Universidade Federal de São Paulo, São Paulo, SP, Brazil.
The brain-derived neurotrophic factor (BDNF) gene plays an important role in modulating the stress-response axis and inflammation, which can be regulated by epigenetic mechanisms. BNDF methylation has been associated with stress-related psychiatric disorders such as depression, anxiety and post-traumatic stress. Previous studies have reported that stressful events are involved with long-lasting alterations in DNA methylation (DNAm) of the BNDF exon IV promoter, suggesting that glucocorticoids and inflammatory cytokines can regulate this process.
View Article and Find Full Text PDFExpression Profiles of Brain-Derived Neurotrophic Factor Splice Variants in the Hippocampus of Alzheimer's Disease Model Mouse.
Biol Pharm Bull
November 2024
Laboratory of Molecular Neuroscience, Faculty of Pharmacy, Takasaki University of Health and Welfare.
Article Synopsis
- Dysregulation of BDNF is linked to Alzheimer's disease, and this study examined its expression in the hippocampus of 5xFAD mice, focusing on sex and age.
- At 3 months, female wild-type mice had higher Bdnf mRNA levels than males, but this difference disappeared in female 5xFAD mice.
- By 6 months, female 5xFAD mice showed a significant decrease in full-length TrkB receptor mRNA while increased levels of truncated TrkB were observed in both sexes, highlighting potential disruptions in BDNF signaling due to Alzheimer's.
- The research indicates that certain Bdnf splice variants are maintained at higher levels in young female mice but may be affected by Alzheimer's
Peptidomimetic inhibitors targeting TrkB/PSD-95 signaling improves cognition and seizure outcomes in an Angelman Syndrome mouse model.
Neuropsychopharmacology
November 2024
Department of Molecular Biology, Cell Biology and Biochemistry, Brown University, Providence, RI, 02912, USA.
Angelman syndrome (AS) is a rare genetic neurodevelopmental disorder with profoundly debilitating symptoms with no FDA-approved cure or therapeutic. Brain-derived neurotrophic factor (BDNF), and its receptor tropomyosin receptor kinase B (TrkB), have a well-established role as regulators of synaptic plasticity, dendritic outgrowth and spine formation. Previously, we reported that the association of postsynaptic density protein 95 (PSD-95) with TrkB is critical for intact BDNF signaling in the AS mouse model, as illustrated by attenuated PLCγ and PI3K signaling and intact MAPK pathway signaling.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!